Intelligence · Clinical Development
Pipeline search results
Programs matching “omid” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 143 pipeline programs matching "omid" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Caudal Dexmedetomidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Inguinal Hernia
1 trial -
Dexmedetomidine
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
Dexmedetomidine
BioXcel Therapeutics
Opioid Withdrawal
1 trial -
Dexmedetomidine injection
Sana Biotechnology
Post Spinal Shivering
1 trial -
Dexmedetomidine sublingual film
BioXcel Therapeutics
Delirium
1 trial -
EAE 115
Wuhan Createrna Science and Technology Co., Ltd
Multiple myeloma patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor"
1 trial -
Ezutromid
Summit Therapeutics
Duchenne Muscular Dystrophy
1 trial -
Fibromun, Temozolomide SUN 100 mg hard capsules
Philogen S.p.A.
Glioblastoma
1 trial -
Induction therapy of GP(Pomalidomide+Obinutuzumab）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indolent Lymphoma
1 trial -
Ixazomib/Pomalidomide/Dexamethasone
Takeda
Multiple Myeloma
1 trial -
Leflunomide
Sanofi Pasteur
Systemic Lupus Eythematosus (SLE)
1 trial -
Leflunomide CF for primary Sjögren's Syndrome
Disc Medicine
primary Sjögren's Syndrome
1 trial -
Lenalidomide
Takeda
Myeloma, Multiple
1 trial -
Lenalidomide
The First People's Hospital of Lianyungang
PTCL, NOS
1 trial -
Lenalidomide
United Therapeutics Europe Ltd
Recurrent Mantle Cell Lymphoma
1 trial -
Lenalidomide [Leavdo®]
Hospital Authority, Hong Kong
Antibiotics-unresponsive MALT Lymphoma
1 trial -
Lenalidomide and Gemcitabine (Dose level 11)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-cell Lymphomas (PTCL)
1 trial -
Lenalidomide combined with G-CHOP (LO CHOP)
The First People's Hospital of Lianyungang
DLBCL - Diffuse Large B Cell Lymphoma
1 trial -
Luspatercept combined with low-dose thalidomide
The First People's Hospital of Lianyungang
Transfusion-dependent β-thalassemia Patients
1 trial -
MyDRUG (MMRC-085)
Karyopharm Therapeutics Inc
Relapsed Refractory Multiple Myeloma
1 trial -
Pomalidomide
Celgene Europe Limited
Multiple Myeloma
1 trial -
RITUXIMAB, Golcadomide
Fondazione Telethon ETS
Diffuse Large B-cells non-Hodgkin Lymphoma
1 trial -
Radiotherapy plus temozolomide
The First People's Hospital of Lianyungang
Glioma (Any Grade) in the Brain
1 trial -
Romidepsin
Takeda
Lymphoma, T-Cell, Peripheral
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.